Quick Takeaways
- BlackRock, Inc. filed SCHEDULE 13G for CANDEL THERAPEUTICS INC Common Stock (CADL).
- Disclosed ownership: 5.2%.
- Date of event: 31 Dec 2025.
BlackRock, Inc. - 31 Dec 2025 SCHEDULE 13G Report for CANDEL THERAPEUTICS INC Common Stock (CADL)
- Filing Manager
- BlackRock, Inc.
- Reporting Manager
- BlackRock, Inc.
- Security
- CANDEL THERAPEUTICS INC Common Stock
- Symbol
- CADL
- Shares outstanding
- 54,992,500 shares
- Disclosed Ownership
- 2,859,610 shares
- Ownership
- 5.2%
- Form type
- SCHEDULE 13G
- Filing time
- 21 Jan 2026, 12:30:34 UTC
- Date of event
- 31 Dec 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"BlackRock, Inc. disclosed 5.2% ownership in CANDEL THERAPEUTICS INC Common Stock (CADL) on 31 Dec 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 21 Jan 2026, 12:30.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| BlackRock, Inc. | 5.2% | 2,859,610 | 2,821,816 | 0 | Spencer Fleming | Managing Director |